Treatment outcomes of regimens containing delamanid within therapy of multiple and extensive drug resistant tuberculosis in the Russian Federation

Treatment outcomes of regimens containing delamanid within therapy of multiple and extensive drug resistant tuberculosis in the Russian Federation

.

Bibliographic Details
Main Authors:	A. O. Maryandyshev, S. M. Lorsanov, Z. B. Khaydarkhanova, S. B. Khunkarsultanov, D. V. Perkhin, O. M. Sveshnikova, A. I. Gayda, V. V. Privolnev
Format:	Article
Language:	Russian
Published:	New Terra Publishing House 2019-12-01
Series:	Туберкулез и болезни лёгких
Online Access:	https://www.tibl-journal.com/jour/article/view/1361

Similar Items

The experience of using delamanid in the Chechen Republic
by: S. M. Lorsanov, et al.
Published: (2020-01-01)

Justification of Chemotherapy Duration in Patients with Multiple and Pre-Extensive Drug Resistant Tuberculosis in the Russian Federation
by: A. I. Gayda, et al.
Published: (2023-01-01)

Delamanid-containing regimens and multidrug-resistant tuberculosis: A systematic review and meta-analysis
by: Mohammad Javad Nasiri, et al.
Published: (2022-11-01)

TREATMENT OF TUBERCULOSIS PATIENTS WITH EXTENSIVE DRUG RESISTANCE USING NEW ANTI-TUBERCULOSIS DRUGS IN THE CIVILIAN COMMUNITY OF ARKHANGELSK REGION
by: Anastasiya I. Gayda, et al.
Published: (2018-08-01)

Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis
by: Andrey Maryandyshev, et al.
Published: (2017-10-01)

Perspectives of targeted chemotherapy with delamanid in the treatment regimens of those with multiple/extensive drug resistant tuberculosis. A success, chance or uncertainty?
by: Aleksey G. Naumov, et al.
Published: (2018-11-01)

Favorable outcome of individual regimens containing bedaquiline and delamanid in drug-resistant tuberculosis: A systematic review
by: Oki Nugraha Putra, et al.
Published: (2023-01-01)

Scoping review: QT interval prolongation in regimen containing bedaquiline and delamanid in patients with drug-resistant tuberculosis
by: Oki Nugraha Putra, et al.
Published: (2022-01-01)

Early experience of delamanid in extensively drug-resistant pulmonary tuberculosis
by: Vikas Marwah, et al.
Published: (2023-01-01)

Injectable-free regimens containing bedaquiline, delamanid, or both for adolescents with rifampicin-resistant tuberculosis in Khayelitsha, South Africa
by: Erika Mohr-Holland, et al.
Published: (2020-03-01)

Culture conversion at six months in patients receiving bedaquiline- and delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis
by: Shynar M. Maretbayeva, et al.
Published: (2021-12-01)

Effectiveness and cardiovascular safety of delamanid-containing regimens in adults with multidrug-resistant or extensively drug-resistant tuberculosis: A nationwide cohort study from Belarus, 2016-18
by: Vera Auchynka, et al.
Published: (2021-01-01)

Effectiveness and safety of delamanid- or bedaquiline-containing regimens among children and adolescents with multidrug resistant or extensively drug resistant tuberculosis: A nationwide study from Belarus, 2015-19
by: Varvara Solodovnikova, et al.
Published: (2021-01-01)

Delamanid is a new anti-tuberculosis drug: use, limitations, and prospects
by: V. N. Zimina, et al.
Published: (2021-03-01)

Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Children: The Role of Bedaquiline and Delamanid
by: Francesco Pecora, et al.
Published: (2021-05-01)

Profile of delamanid for the treatment of multidrug-resistant tuberculosis
by: Szumowski JD, et al.
Published: (2015-01-01)

The role of delamanid in the treatment of drug-resistant tuberculosis
by: Lewis JM, et al.
Published: (2015-05-01)

Comparative effectiveness of adding delamanid to a multidrug-resistant tuberculosis regimen comprised of three drugs likely to be effective.
by: Carly A Rodriguez, et al.
Published: (2023-01-01)

Prevalence of Mycobacterium tuberculosis resistant to bedaquiline and delamanid in China
by: Wencong He, et al.
Published: (2021-09-01)

TUBERCULOSIS WITH MULTIDRUG-RESISTANT AND EXTENSIVELY DRUG-RESISTANT OF MICOBACTERIUM TUBERCULOSIS IN THE RUSSIAN FEDERATION
by: A.E. ERGESHOV, et al.
Published: (2018-08-01)

Treatment outcomes of extensive drug resistant tuberculosis in the penitentiary system of the Russian Federation
by: S. A. Sterlikov, et al.
Published: (2018-11-01)

Delamanid expanded access novel treatment of drug resistant tuberculosis
by: Rustomjee R, et al.
Published: (2015-10-01)

Is a 6-month Treatment for Isoniazid-resistant Tuberculosis Effective?
by: A. I. Kulizhskaya, et al.
Published: (2022-03-01)

Treatment Outcomes of Fluoroquinolone-Resistant Multidrug-Resistant Tuberculosis: An Implication for Delamanid
by: Oki Nugraha Putra, et al.
Published: (2024-04-01)

Delamanid expanded access novel treatment of drug resistant tuberculosis [Corrigendum]
by: Rustomjee R, et al.
Published: (2016-04-01)

Cost-effectiveness of bedaquiline or delamanid plus background regimen for multidrug-resistant tuberculosis in a high-income intermediate burden city of China
by: Qianqian Fan, et al.
Published: (2019-01-01)

Tuberculosis features in federal districts of the Russian Federation
by: V. A. Astafyev, et al.
Published: (2017-09-01)

New developments in the treatment of drug-resistant tuberculosis: clinical utility of bedaquiline and delamanid
by: Brigden G, et al.
Published: (2015-10-01)

Validating a 14-drug microtitre plate containing bedaquiline and delamanid for large-scale research susceptibility testing of Mycobacterium tuberculosis
by: Rancoita, PMV, et al.
Published: (2018)

Evaluation of the effectiveness of bedaquiline and delamanid treatment among children and adolescents with multi-drug-resistant pulmonary tuberculosis
by: M.I. Sakhelashvili, et al.
Published: (2023-03-01)

Corrigendum to ‘Culture conversion at six months in patients receiving bedaquiline- and delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis’ International Journal of Infectious Diseases Volume 113S1 (2021) S91-S95
by: Shynar M. Maretbayeva, et al.
Published: (2022-08-01)

Treatment Outcomes of Fluoroquinolone- Resistant Multidrug-Resistant Tuberculosis: An Implication for Delamanid - Authors’ Reply
by: Saerom Kim, et al.
Published: (2024-04-01)

Advances of new drugs bedaquiline and delamanid in the treatment of multi-drug resistant tuberculosis in children
by: Hanzhao Zhu, et al.
Published: (2023-06-01)

Genetic diversity of candidate loci linked to Mycobacterium tuberculosis resistance to bedaquiline, delamanid and pretomanid
by: Paula J. Gómez-González, et al.
Published: (2021-09-01)

Interim treatment outcomes in multidrug-resistant tuberculosis patients treated sequentially with bedaquiline and delamanid
by: Hoon Hee Lee, et al.
Published: (2020-09-01)

Assessment of effectiveness of the empiric treatment regimen in tuberculosis patients suspected with multiple drug resistance in the Russian Federation
by: Sergey A. Sterlikov, et al.
Published: (2018-11-01)

Bedaquiline, Delamanid, Linezolid, Clofazimine, and Capreomycin MIC Distributions for Drug Resistance Mycobacterium tuberculosis in Shanghai, China
by: Guo Y, et al.
Published: (2023-12-01)

The Activities and Secretion of Cytokines Caused by Delamanid on Macrophages Infected by Multidrug-Resistant Mycobacterium tuberculosis Strains
by: Xia-Li Lyu, et al.
Published: (2021-12-01)

Mechanism of Action, Resistance, Synergism, and Clinical Implications of Delamanid Against Multidrug-Resistant Mycobacterium tuberculosis
by: Saeed Khoshnood, et al.
Published: (2021-10-01)

EFFICIENCY AND SAFETY OF CHEMOTHERAPY REGIMEN WITH SQ109 IN THOSE SUFFERING FROM MULTIPLE DRUG RESISTANT TUBERCULOSIS
by: S. E. Borisov, et al.
Published: (2018-04-01)